Amylyx Pharmaceuticals, Inc.
AMLX
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.8B
$34.10
▲ +0.41%
P/E
-24.18
Mkt Cap
$3.8B
52-Wk Range
$10.07–$41.14
52-Week Range
$10.07 - $41.14
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 226.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Dual-mechanism UPR-Bax apoptosis inhibitor technology with differentiated mechanism of action
- Early-stage pipeline positioned in high-unmet-need neurodegenerative disease markets
- Experienced management team with deep expertise in neurology and drug development
Bear Case
1 risk
- Low volatility (beta -0.2).
Growth
Stable outlook
Clinical trial progression and regulatory approvals for AMX0035 in ALS and other indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+162.1% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying AMLX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.39 vs -$0.36 consensus (-8.1% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-8.1%
Revenue trend · last 8Q
—
-101%
-100%
—
-100%
—
—
—
Q2 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
-$1.0M
-$665.0K
$0
$0
$0
$0
$0
$0
Margins · last 8Q
Gross
—
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 3, 2026
vs Industry
How AMLX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related